GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (ASX:ACW) » Definitions » EV-to-EBITDA

Actinogen Medical (ASX:ACW) EV-to-EBITDA : -5.88 (As of Dec. 01, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Actinogen Medical's enterprise value is A$74.10 Mil. Actinogen Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-12.60 Mil. Therefore, Actinogen Medical's EV-to-EBITDA for today is -5.88.

The historical rank and industry rank for Actinogen Medical's EV-to-EBITDA or its related term are showing as below:

ASX:ACW' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.67   Med: -0.91   Max: -0.03
Current: -5.88

During the past 13 years, the highest EV-to-EBITDA of Actinogen Medical was -0.03. The lowest was -7.67. And the median was -0.91.

ASX:ACW's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.19 vs ASX:ACW: -5.88

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-01), Actinogen Medical's stock price is A$0.027. Actinogen Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.006. Therefore, Actinogen Medical's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Actinogen Medical EV-to-EBITDA Historical Data

The historical data trend for Actinogen Medical's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinogen Medical EV-to-EBITDA Chart

Actinogen Medical Annual Data
Trend Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.07 -57.81 -8.10 -6.22 -12.47

Actinogen Medical Semi-Annual Data
Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.10 - -6.22 - -12.47

Competitive Comparison of Actinogen Medical's EV-to-EBITDA

For the Biotechnology subindustry, Actinogen Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinogen Medical's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's EV-to-EBITDA falls into.



Actinogen Medical EV-to-EBITDA Calculation

Actinogen Medical's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=74.100/-12.604
=-5.88

Actinogen Medical's current Enterprise Value is A$74.10 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Actinogen Medical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-12.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actinogen Medical  (ASX:ACW) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Actinogen Medical's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.027/-0.006
=At Loss

Actinogen Medical's share price for today is A$0.027.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Actinogen Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.006.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Actinogen Medical EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinogen Medical Business Description

Traded in Other Exchanges
Address
109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.

Actinogen Medical Headlines

From GuruFocus

Stocks That Are Making A Good Come Back

By reports.droy reports.droy 03-10-2015

Accuride Corporation: Earnings Report For Q2 2014

By Black Iguana Nitish 10-13-2014